Intuitive Surgical, Inc. (NASDAQ:ISRG) Holdings Decreased by Greenup Street Wealth Management LLC

Greenup Street Wealth Management LLC reduced its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 14.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 547 shares of the medical equipment provider’s stock after selling 91 shares during the quarter. Greenup Street Wealth Management LLC’s holdings in Intuitive Surgical were worth $269,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Mirador Capital Partners LP raised its stake in shares of Intuitive Surgical by 1.4% during the third quarter. Mirador Capital Partners LP now owns 3,526 shares of the medical equipment provider’s stock valued at $1,732,000 after purchasing an additional 50 shares in the last quarter. Advisors Asset Management Inc. raised its stake in shares of Intuitive Surgical by 18.1% during the first quarter. Advisors Asset Management Inc. now owns 7,380 shares of the medical equipment provider’s stock valued at $2,945,000 after purchasing an additional 1,129 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund raised its stake in shares of Intuitive Surgical by 617.1% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 89,069 shares of the medical equipment provider’s stock valued at $39,622,000 after purchasing an additional 76,649 shares in the last quarter. Brookstone Capital Management raised its stake in shares of Intuitive Surgical by 22.4% during the second quarter. Brookstone Capital Management now owns 12,530 shares of the medical equipment provider’s stock valued at $5,340,000 after purchasing an additional 2,289 shares in the last quarter. Finally, M&G Plc raised its stake in shares of Intuitive Surgical by 53.5% during the second quarter. M&G Plc now owns 5,069 shares of the medical equipment provider’s stock valued at $2,256,000 after purchasing an additional 1,766 shares in the last quarter. 83.64% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Piper Sandler lifted their price objective on shares of Intuitive Surgical from $490.00 to $495.00 and gave the company an “overweight” rating in a research note on Friday, July 19th. BTIG Research lifted their target price on Intuitive Surgical from $494.00 to $518.00 and gave the stock a “buy” rating in a report on Monday. Stifel Nicolaus lifted their target price on Intuitive Surgical from $430.00 to $475.00 and gave the stock a “buy” rating in a report on Friday, July 19th. Raymond James lifted their target price on Intuitive Surgical from $500.00 to $540.00 and gave the stock an “outperform” rating in a report on Monday. Finally, Citigroup lifted their target price on Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a report on Thursday, August 22nd. Six analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $484.15.

Intuitive Surgical Stock Down 0.6 %

Shares of NASDAQ:ISRG opened at $473.73 on Friday. The firm has a fifty day moving average of $482.69 and a two-hundred day moving average of $436.91. The firm has a market capitalization of $168.03 billion, a P/E ratio of 85.51, a price-to-earnings-growth ratio of 5.40 and a beta of 1.39. Intuitive Surgical, Inc. has a 12-month low of $254.85 and a 12-month high of $496.48.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.24. The company had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The company’s revenue for the quarter was up 14.5% on a year-over-year basis. During the same quarter last year, the business posted $1.18 EPS. Equities research analysts expect that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current fiscal year.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, Director Craig H. Barratt sold 1,400 shares of Intuitive Surgical stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $458.13, for a total transaction of $641,382.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Intuitive Surgical news, Director Craig H. Barratt sold 1,400 shares of Intuitive Surgical stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $458.13, for a total transaction of $641,382.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Robert Desantis sold 376 shares of the firm’s stock in a transaction on Monday, July 29th. The shares were sold at an average price of $446.60, for a total transaction of $167,921.60. Following the transaction, the executive vice president now owns 5,506 shares in the company, valued at $2,458,979.60. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 53,120 shares of company stock valued at $25,528,753 in the last quarter. Company insiders own 0.90% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.